NCT07818460Not yet recruiting
Risk Factors and Prognosis of Autism Spectrum Disorder
Risk Factors and Prognosis of Autism Spectrum Disorder in Children Attending Assiut University Children's Hospital
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
This case-control study with prospective follow-up aims to identify risk factors associated with autism spectrum disorder and to evaluate the prognosis of children with ASD attending Assiut University Children's Hospital.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 84 (estimated)
- First submitted
- 8 Sept 2026
- Start date
- 10 Sept 2026
- Primary completion date
- 20 Sept 2027
- Lead sponsor
- Assiut University
- Diseases
- Autism
- NCT number
- NCT07818460
What you commit to
- Study type: Observational
- Planned participants: 84
- From 10 Sept 2026 to the primary completion date, 20 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known chromosomal or genetic syndrome associated with secondary autistic features (e.g., Fragile X, Down syndrome), unless studied as a separate subgroup
Age
- Age below 3 years or above 17 years
Other
- Incomplete medical records
- Refusal of parents/guardians to participate
- Loss to follow-up before the minimum 6-month prognostic assessment
Who the study is looking for
- Age 3 to 17 years
- Confirmed diagnosis of ASD according to DSM-5 criteria, supported by standardized tools (e.g., CARS)
- Parent or legal guardian able and willing to provide informed consent
- \- Age- and sex-matched children without ASD or other neurodevelopmental disorders
Age in the registry: 3 years to 17 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.